Gilenya (generic name: fingolimod) is a new class of medication for treatment of various forms of relapsing multiple sclerosis (MS) in patients ten years of age and older. This includes clinically isolated syndrome (CIS) which refers to the first episode of MS symptoms, relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS). With SPMS the level of disability gets steadily worse and there are likely to be further relapses.
Fingolimod is known as a sphingosine 1-phosphate receptor modulator, which acts to retain lymphocytes within the lymph nodes. This then limits those cells from crossing the blood-brain barrier in the central nervous system (CNS) which reduces the level of inflammatory damage to nerve cells.
Gilenya was also approved for treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), which is an acquired autoimmune disease of the peripheral nervous system characterized by progressive weakness and impaired sensory function in the legs and arms. CIDP is the chronic form of active Guillain-Barré syndrome.
Reviews
There are no reviews yet.